Company Profiles

driven by the PitchBook Platform

BliNK Therapeutics

BliNK Therapeutics
2011 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Accelerator/Inc LATEST DEAL TYPE
3 INVESTORS
Description

Developer of novel platform to generate therapeutic and diagnostic monoclonal antibodies towards clinically relevant targets. The company has developed a technology which provides a new way to activate the immune system's B cells to produce antibodies in response to a specific antigen.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
London
England
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore BliNK Therapeutics’s full profile, request a free trial.

BliNK Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 00.000 Completed Startup
2. Early Stage VC 01-Jan-2015 00000 00.000 00.000 Completed Startup
1. Seed Round 13-Jun-2011 $1.79M $1.79M 00.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

BliNK Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Ordinary 000 00000.00 00000.00 00 00000.00 00.000
To view this company’s complete Cap Table, request access »

BliNK Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Cancer Research Technology Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Stevenage Bioscience Catalyst Accelerator/Incubator 000 0000 000000 0

BliNK Therapeutics Board Members (2)

Name Representing Role Since Contact
Info
Irina Staatz-Granzer Self Chairman 000 0000
Nicola Beltraminelli Ph.D Self Board Member 000 0000
Questions or concerns about this profile? Reach out to website-support@pitchbook.com